Clinical trials: Oligoprogressive
Prostate Cancer (Adenocarcinoma), OligoProgressive Metastatic Disease
The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
In patients with metastatic prostate cancer (PCa) who receive androgen deprivation therapy (ADT), the sensitivity to castration will eventually disappear due to the selection of castration-refractory clones.
- Conditions
- Prostate Cancer (Adenocarcinoma), OligoProgressive Metastatic Disease, Castration Resistant Metastatic Prostate Cancer, Radiotherapy
- Trial name
- OLYMPIAN (NCT07038304)
- Testing
- Metastasis directed radiotherapy
- Where
- 2 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- University Medical Center Groningen
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT
At the moment there is a lack of data in the setting of oligometastatic PC in particular regarding the interaction between ablative SBRT, ADT and patient's immune system response.
- Trial name
- IOSCAR (NCT04624828)
- Testing
- Radiotherapy, androgen deprivation therapy (ADT), immune evaluation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Istituto Clinico Humanitas
Non Small Cell Lung Cancer, Oligoprogressive
Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma
This is a randomized phase II study designed to evaluate the effect of local consolidative radiation therapy (LCT) to all sites of oligoprogressive disease in patients with metastatic non-small cell lung carcinoma who have…
- Trial name
- NCT04485026
- Testing
- Local consolidative radiation therapy, Standard of care radiation therapy
- Sponsor
- Wake Forest University Health Sciences
Castration-resistant Prostate Cancer, Oligoprogressive
Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.
- Trial name
- MEDCARE (NCT06585007)
- Testing
- Radiotherapy, metastasectomy
- Where
- Belgium
- Volunteers
- 246 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
The goal of this clinical trial is to learn if Stereotactic Body Radiotherapy (SBRT) can treat the oligo-progressive metastatic non-small cell lung cancer (NSCLC) after first-line chemotherapy.
- Conditions
- Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV, OligoProgressive Metastatic Disease
- Trial name
- OPPRESS (NCT06523673)
- Testing
- Stereotactic Body Radiotherapy, second-line systemic therapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Oligoprogressive Renal Cell Carcinoma
SAbR For Oligo-Progressive Renal Cell Cancer.
Metastatic kidney cancer patients on systemic therapy often develop resistance to limited sites that leads to changing of the systemic therapy.
- Trial name
- NCT03696277
- Testing
- Stereotactic ablative body radiation (SABR)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Texas Southwestern Medical Center
Oligoprogressive, Castration-Resistant Prostate Cancer
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment of oligoprogressive metastases.
- Trial name
- NCT04838899
- Testing
- Stereotactic Body Radiation Therapy (SABR)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Non-small Cell Lung Cancer, Oligoprogressive
A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression
This Phase II randomized study is to explore the efficacy and safety of Furmonertinib combined with radiotherapy for non-small cell lung cancer with oligoprogression after first-line EGFR-TKI therapy.
- Trial name
- NCT04970693
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sun Yat-sen University